Access for Cancer Treatment - 2018
•Download as PPTX, PDF•
0 likes•4 views
Executive Summary for Access to Cancer Treatment
Recommended
Recommended
More Related Content
Similar to Access for Cancer Treatment - 2018
Similar to Access for Cancer Treatment - 2018 (20)
Recently uploaded
Recently uploaded (20)
Access for Cancer Treatment - 2018
- 1. Access for Cancer Treatment: Public & Private Market Efraim Ariesandy/FEB 2018
- 2. BUSSINES CASE • Considering that public funding might be more challenging in the next upcoming years in Indonesia. This business case seeks to address the increased trend of delayed access to cancer medicines in Indonesia. • Create the idea is to set-up a ‘funding navigator’ service to help patients access funding to cover the cost of cancer medicines not being covered under BPJS (Universal Health Coverage).
- 3. Opportunities & Challenges PUBLIC • JKN creates separate funding for cancer treatment (MC & FFS) • Pricing pressure from Government Procurement Agency (LKPP) • Alignment & Collaboration amongst stakeholders • Integrated early-detection program PRIVATE • The needs for premium healthcare service • Increase health (disease) awareness, including on health insurance • Support & strengthen business along with public sector
- 4. Access on Cancer Medicine: Prediction based on existing regulations & JKN current situation Type of Medicine REGULATORY APPROVAL NATIONAL FORMULAR Y PRICE PRESSURE ACCES STRATEGY NEW IN CLASS HIGH MED MED-LOW HIGH-MED COMPETITTOR EXISTED MED-LOW LOW HIGH-MED MED ADVANCED INDICATION MED-LOW MED MED HIGH-MED BIOSIMILIAR AVAILABILITY MED-LOW MED HIGH-MED MED
- 5. Access Strategy INTERNAL • Good common knowledge about UHC & government procurement • Cross-functional collaboration • The right VP & Pricing strategy • Strive to strengthen partnership with stakeholders (consider for a long-term) • Expand engagement to tape the shift in stakeholder landscape • Identify public opportunity with agility and innovative way of thinking EXTERNAL
- 6. OBJECTIVES: • for early and expanding access of cancer patient • support government program/JKN • commercial drive Type of Access Program Early Access HTA (limited) Risk Sharing Managed Entry Agreement (MEA) Cost Sharing Outcome Research/R WE DIGITAL Initiatives Education & Awareness Program Patient Registry Budget Impact Model
- 8. THANK YOU
Editor's Notes
- PUBLIC JKN implementation creates separate funding for cancer treatment (MC & FFS) Pricing pressure from Government Procurement Agency (LKPP) – create opportunity for HTA Alignment & Collaboration amongst stakeholders need to be improved – 1)MOH, BPJS, LKPP (Procurement, database, demand/supply); 2)Clinical Pathway 3)Other Institution/Private collaboration (YLKI, MOF, TNP2K, Academy, Pts registry, Risk Sharing); digital healthcare, BIG data, data integrity Shared data base of four-years JKN – BPJS mainly vs FASKES Integrated early detection program PRIVATE The needs for premium healthcare service Increase health (disease) awareness, including on health insurance Support & strengthen business along with public sector